Let’s Improve the Quality of Lives Together
At Processa, we develop drugs with a high potential return on investment and are designed to de-risk programs efficiently by targeted study and careful execution of clinical trials. We focus on drugs that have clinical evidence of efficacy and treat conditions with a high unmet medical need.
We actively seek drug development opportunities that address unmet needs (preferably at a clinical stage of development) where we can apply our risk abated development strategy to provide design, development and execution of clinical study.
We will identify sales, marketing and distribution partners at the appropriate stage of development to commercially launch our products.
In-licensing
We have licensed in the following products:
- PCS6422 from Elion Oncology, Inc.
- PCS499 from CoNCERT Pharmaceuticals, Inc.
- PCS12852 from Yuhan Corporation
- PCS11T from Aposense, LTD
- PCS3117 from Ocuphire Pharma, Inc.
Partnering
Consistent with the shift in priority, including the allocation of resources to our NGC drugs, Processa has begun and will continue to meet with potential licensing partners, as well as pursue other options to monetize PCS12852 and PCS499. If you are interested in speaking with us on these or other products, please contact us.
Ready to Partner Up?
Contact us with your questions about licensing, co-development, or other possibilities.